Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced the publication of Phase IIIb trial results for LINZESS (linaclotide) in the American Journal of Gastroenterology. The study demonstrated that 290 mcg of linaclotide significantly improved abdominal symptoms among adults with irritable bowel syndrome with constipation (IBS-C). Results showed a 29.7% decrease in abdominal scores compared to an 18.3% decrease with placebo, starting from week one. LINZESS was well-tolerated, with diarrhea being the most common adverse effect. The findings aim to enhance patient-doctor communication concerning IBS-C symptoms.
Ironwood Pharmaceuticals (NASDAQ: IRWD) has appointed Thomas McCourt as permanent CEO, having served as interim CEO since March 2021. His leadership aims to drive growth for LINZESS (linaclotide), a leading treatment for gastrointestinal conditions. Additionally, Gina Consylman will step down as CFO effective July 2, 2021, without any reported disagreements. The board commended her contributions, particularly during Ironwood's strategic transactions. McCourt expressed confidence in the company's financial stability and its future opportunities in the GI healthcare sector.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced an agreement with Teva Pharmaceuticals to license a generic version of LINZESS (linaclotide), allowing marketing to begin on March 31, 2029, pending FDA approval. This agreement settles all known ANDA filings for generic LINZESS. The patent coverage for LINZESS is preserved across three dosage strengths, reaffirming the company's plans to grow its franchise. The settlement will be submitted for review to regulatory authorities.
Summary not available.
Summary not available.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has authorized a new share repurchase program allowing for the buyback of up to $150 million of its outstanding shares through December 2022. This initiative reflects Ironwood's disciplined capital allocation strategy and confidence in its financial position. The company aims to return cash to shareholders while continuing to focus on maximizing revenues from LINZESS® and developing innovative treatments for GI diseases. Management will determine the timing and method of repurchases based on market conditions.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported strong first quarter 2021 results, with total revenues of $88.8 million, up 11% from $79.9 million in Q1 2020. LINZESS prescription demand grew 12% year-over-year, contributing to net sales of $215.4 million. GAAP net income surged to $39.9 million or $0.25 per share, compared to $3.3 million or $0.02 per share last year. Operating expenses decreased significantly to $43.4 million. Ironwood ended Q1 with $438.5 million in cash and cash equivalents, positioning itself well for future investments.
Ironwood Pharmaceuticals (NASDAQ: IRWD) has announced its first quarter 2021 investor update conference call and webcast scheduled for May 6, 2021, at 8:30 a.m. Eastern Time. Interested participants can join by calling (833) 350-1432 for U.S. and Canada, or (647) 689-6932 internationally, using conference ID 8067476. A replay will be available after 11:30 a.m. on the same day until May 20, 2021. Ironwood focuses on developing treatments for gastrointestinal diseases, with linaclotide being a key product for IBS-C and CIC.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will present at three major investor conferences in February and March 2021:
- SVB Leerink Global Healthcare Conference on February 26 at 8:00 a.m. EST
- Cowen Annual Health Care Conference on March 2 at 11:10 a.m. EST
- Barclays Global Healthcare Conference on March 9 at 3:35 p.m. EST
Investors can access live webcasts through the company's website, with replays available for 14 days after each conference. Ironwood specializes in GI-related healthcare, notably its leading treatment for IBS-C and CIC.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its fourth quarter and full year 2020 results, highlighting significant growth in LINZESS net sales, which rose 10% year-over-year despite COVID-19 challenges. Total revenues for the fourth quarter were $116.7 million, down from $126.3 million in 2019, while full-year revenues decreased to $389.5 million from $428.4 million. Despite these declines, Ironwood reported a GAAP net income of $106.2 million for 2020, compared to $21.5 million in 2019. The company anticipates LINZESS net sales growth of 3-5% in 2021.